A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer (RAINFALL)
The main purpose of this study is to evaluate the effectiveness of ramucirumab, which is a targeted antibody, in combination with capecitabine and cisplatin compared to capecitabine and cisplatin alone in participants with stomach cancer.
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participant must have a confirmed diagnosis of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
Participant must have adequate organ function
Participant must agree to provide a tumor tissue sample
Participants Must Not:
Participant must not have received any prior first-line systemic therapy (however, prior adjuvant or neo-adjuvant therapy is permitted)
Participant must not have adenocarcinoma of the esophagus
Participant must not have human epidermal growth factor receptor 2 (HER2) positive status
Participant must not be receiving long term therapy with nonsteroidal anti-inflammatory agents (NSAIDs), however aspirin use at doses up to 325 mg/day is permitted
Participant must not have uncontrolled high blood pressure prior to initiating study treatment
Female participant must not be pregnant or lactating
Lilly Trial Alerts
You will complete the questionnaire on another website.YesNo